Ah well, I didn't say anything about profit, did I? Just utilisation. There may well be un-forecasted additional investment in building/fit-out new capacity, as well as differences between contracted utilisation and billable utilisation. Also we don't know the price/MW achieved in any new sales.
However, I agree that the existing forecasts for the FY look conservative/achievable, based on the single data point of P1 utilisation growth.
My investment in NXT has always been more of a longer-term one, based on a 3-5 year view of a regular annuity-style income for fully-utilised existing capacity. But if existing capacity gets utilised quicker, that accelerates the 3-5 year view into perhaps 2-4 years.
I am also encouraged by tie-ups with other major players including Microsoft, Telstra etc which position NXT as a respected player in this space. As well as those mysterious fibre-optic cables APX-West and APX-East which terminate / connect at P1.
- Forums
- ASX - By Stock
- NXT
- Latest analyst forecasts
NXT
nextdc limited
Add to My Watchlist
1.05%
!
$14.19

Latest analyst forecasts, page-17
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$14.19 |
Change
-0.150(1.05%) |
Mkt cap ! $9.087B |
Open | High | Low | Value | Volume |
$14.51 | $14.63 | $14.17 | $35.40M | 2.482M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 32553 | $14.19 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$14.28 | 100 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 420 | 14.160 |
5 | 2064 | 14.100 |
1 | 2000 | 14.030 |
1 | 2000 | 14.020 |
2 | 284 | 14.010 |
Price($) | Vol. | No. |
---|---|---|
14.450 | 200 | 1 |
14.590 | 1000 | 1 |
14.600 | 500 | 1 |
14.640 | 500 | 1 |
14.690 | 687 | 1 |
Last trade - 16.15pm 27/06/2025 (20 minute delay) ? |
Featured News
NXT (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online